Additional file 2: Table S1. of Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes

Characterization of bufalin-loaded liposomes and bufalin-loaded PEGylated liposomes. Table S2. Inhibition of bufalin on six kinds of tumor cell lines. (DOCX 14 kb

Additional file 3: Figure S2. of Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes

Characteristic chromatogram of bufalin in plasma. (a) Blank plasma. (b) Blank plasma spiked with bufalin. (c) Blank plasma spiked with bufalin and resibufogenin (as internal standard). (d) Plasma samples spiked with resibufogenin 30 min after intravenous administration of bufalin entity. (e) Plasma samples spiked with resibufogenin 30 min after intravenous administration of bufalin-loaded liposomes. (f) Plasma samples spiked with resibufogenin 30 min after intravenous administration of bufalin-loaded PEGylated liposomes. (1) Bufalin; (2) Resibufogenin. (TIFF 1372 kb

Additional file 1: Figure S1. of Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes

The molecular formulas of the substances used in the formulation. (JPEG 103 kb